**Contents**

**BREAKING ADVANCES**
4595  Highlights from Recent Cancer Literature

**OBITUARY**
4597  Emil Frei III, MD: In Memoriam (1924–2013)

**REVIEWS**
4599  A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Nicholas Mitsiades

4606  Myeloid-Derived Suppressor Cells as Osteoclast Progenitors: A Novel Target for Controlling Osteolytic Bone Metastasis
Anandi Sawant and Selvarangan Ponnazhagan

**PERSPECTIVE**
4611  Cancer Research Advocacy: Past, Present, and Future
Jane Perlmutter, Shannon K. Bell, and Gwen Darien

**INTEGRATED SYSTEMS AND TECHNOLOGIES**
4616  Quantitative In Vivo Characterization of Intracellular and Extracellular pH Profiles in Heterogeneous Tumors: A Novel Method Enabling Multiparametric pH Analysis
Norbert W. Lutz, Yann Le Fur, Johanna Chiche, Jacques Pouyssegur, and Patrick J. Cozzone

**MICROENVIRONMENT AND IMMUNOLOGY**
4629  Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Isabelle Le Mercier, Dominique Poujol, Amélie Sanlaville, Vanja Sisirak, Michael Gobert, Isabelle Durand, Bertrand Dubois, Isabelle Treilleux, Jacqueline Marvel, Jaromir Vlach, Jean-Yves Blay, Nathalie Bendriss-Vermare, Christophe Caux, Isabelle Puisieux, and Nadège Goutagny

**Precisé:** This study suggests a new use in breast cancer treatment for synthetic ligands of TLR7 like imiquimod that are used widely as immunomodulators in clinic.

4641  Vaccine-Instructed Intratumoral IFN-γ Enables Regression of Autochthonous Mouse Prostate Cancer in Allogeneic T-Cell Transplantation
Rodrigo Hess Michelini, Teresa Manzo, Tabea Sturmheit, Veronica Basso, Martina Rocchi, Massimo Freschi, Joanna Listopad, Thomas Blankenstein, Matteo Bellone, and Anna Mondino

**Precisé:** Findings argue that cancer vaccines that improve antitumor T-cell responses can cooperate strongly with allogeneic bone marrow transplants to convert them into effective treatments for solid tumors.

4653  IL-18–Primed Helper NK Cells Collaborate with Dendritic Cells to Promote Recruitment of Effector CD8+ T Cells to the Tumor Microenvironment
Jeffrey L. Wong, Erik Berk, Robert P. Edwards, and Pawel Kalinski

**Precisé:** Results advance understanding of how NK cells can provide an initial stimulus to orchestrate the attraction of dendritic cells and additional effector cells into the cancer microenvironment.

4663  Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Diane Goër, Caroline Flament, Sylvie Busakiewicz, Vichnou Puier-Colame, Oliver Kepp, Isabelle Martins, Julien Pesquet, Alexander Eggermont, Dominique Elias, Nathalie Chaput, and Laurence Zitvogel

**Precisé:** This study reports a comprehensive dissection of the immunomodulatory effects of a bispecific mAb specific for a widely expressed tumor cell adhesion molecule and the T-cell molecule CD3, which is one of the first bispecific mAbs to be explored in clinic.
Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer


Précis: Defining the spatial and temporal factors that limit drug targeting in five tumours could help optimize the preclinical development of new therapeutic agents.

PLZF Confers Effector Functions to Donor T Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD

Arnab Ghosh, Amanda M. Holland, Yildirim Dogan, Nury L. Yim, Uttam K. Rao, Lauren F. Young, Mallory L. West, Natalie V. Singer, Hae Lee, Il-Kang Na, Jennifer J. Tsai, Robert R. Jeng, Olaf Penack, Alan M. Hanash, Cecilia Lezcano, George F. Murphy, Chen Liu, Michel Sadelerain, Martin G. Sauer, Derek San’tAngelo, and Marcel R.M. van den Brink

Précis: This study describes a strategy to improve the qualities of adoptive cell therapies that use alloreactive T cells for immune treatment of cancer, focusing particularly on the reduction of undesirable graft-versus-host side effects.

Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy

Deanna M. Janzen, Miguel A. Rosales, Daniel Y. Paik, Daniel S. Lee, Daniel A. Smith, Owen N. Witte, M. Luisa Iruela-Arispe, and Sanaz Memarzadeh

Précis: Striking findings show that the efficacy of hormonal therapy in endometrial cancer is not related to effects on cancer cells, but rather to effects on stromal cells where the progesterone receptor is necessary and sufficient to mediate antitumor effects in the microenvironment.

MOLECULAR AND CELLULAR PATHOBIOLOGY

Histone Demethylase RBP2 Promotes Lung Tumorigenesis and Cancer Metastasis

Yu-Ching Teng, Cheng-Feng Lee, Ying-Shinan Li, Yi-Ren Chen, Pei-Wen Hsiao, Meng-Yu Chan, Feng-Mao Lin, Hsien-Da Huang, Yen-Ting Chen, Yung-Ming Jeng, Chih-Hung Hsu, Qin Yan, Ming-Daw Tsai, and Li-Jung Juan

Précis: Findings establish an oncogenic function in lung cancer that modifies chromatin, with implications for malignant progression in this tissue.

Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma

Kyle Muir, Antonius Hazim, Ying He, Marion Peyressatre, Do-Young Kim, Xiaoling Song, and Laura Beretta

Précis: This study reveals a role for lipid-modifying enzymes in liver cancer, identifying in particular a specific type of long-chain polyunsaturated fatty acid participating in nonalcoholic steatohepatitis and liver cancer risk.

Posttranscriptional Regulation of PER1 Underlies the Oncogenic Function of IRE1α


Précis: Circadian rhythms that may affect chemotherapeutic efficacy are linked here for the first time to the unfolded protein response, a signaling pathway widely activated in cancer that plays an important role in tumor aggressiveness.

Peroxiredoxin-2 Represses Melanoma Metastasis by Increasing E-Cadherin/β-Catenin Complexes in Adherens Junctions

Doo Jae Lee, Dong Hoon Kang, Mina Choi, Yang Ji Choi, Joo Young Lee, Joo Hyun Park, Yoon Jung Park, Kyung Wha Lee, and Sang Won Kang

Précis: In discovering a specific antioxidant enzyme that can repress melanoma metastasis, this study also suggests a tractable new direction to treat this deadly disease.

TR3 Modulates Platinum Resistance in Ovarian Cancer

Andrew J. Wilson, Annie Y. Liu, Joseph Roland, Oluwafumilayo A. Adedayo, Sarah A. Fletcher, James C. Slaughter, Jeannette Saskowski, Marta A. Crispens, Howard W. Jones III, Samuel James, Oluwode Fadare, and Dimeo Khabele

Précis: There remains great interest in determining general strategies to overcome resistance to platinum compounds that are used very widely to treat cancer, including ovarian cancer.

Cancer Research
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>4770</td>
<td>Genetic Ablation of the Fatty Acid-Binding Protein FABP5 Suppresses HER2-Induced Mammary Tumorigenesis</td>
<td>Liraz Levi, Glenn Lobo, Mary Kathryn Doud, Johannes von Lintig, Darcie Seachrist, Gregory P. Tochrop, and Noa Noy</td>
<td>A protein that delivers fatty acids to the transcription factor PPARY is critical for mammary tumor development, rationalizing the development of FABP5 inhibitors to prevent or treat breast cancer.</td>
</tr>
<tr>
<td>4781</td>
<td>PanIN-Specific Regulation of Wnt Signaling by HIF2α during Early Pancreatic Tumorigenesis</td>
<td>Angela Criscimanna, Li-Juan Duan, Julie A. Rhodes, Volker Fendrich, Emily Wickline, Douglas Hartman, Satdarshan P.S. Monga, Michael T. Lotze, George K. Gittes, Guo-Hua Fong, and Farzad Esni</td>
<td>This study identifies root signaling connections between hypoxia control and the Wnt and Smad4 pathways in early development of pancreatic cancer.</td>
</tr>
</tbody>
</table>

**PREVENTION AND EPIDEMIOLOGY**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>4801</td>
<td>Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer</td>
<td>Yan Wang, Jian Gu, Jack A. Roth, Michelle A.T. Hildebrandt, Scott M. Lippman, Yuqing Ye, John D. Minna, and Xifeng Wu</td>
<td>Accumulating evidence suggests that microRNA signatures derived from blood serum may offer simple quantitative tools for clinical prognosis and therapeutic development in many settings.</td>
</tr>
<tr>
<td>4810</td>
<td>A 20-Year Prospective Study of Plasma Prolactin as a Risk Marker of Breast Cancer Development</td>
<td>Shelley S. Tworoger, A. Heather Eliassen, Xuehong Zhang, Jing Qian, Patrick M. Sloss, Bernard A. Rosner, and Susan E. Hankinson</td>
<td>Elevated levels of plasma prolactin are associated with an increased risk of breast cancer, but only for 10 years after assessment of this risk marker, supporting a role for prolactin at later stages in breast carcinogenesis.</td>
</tr>
</tbody>
</table>

**THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>4820</td>
<td>Novel Recombinant Human B7–H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses</td>
<td>Denarda Dangaj, Evripidis Lanitis, Aizhi Zhao, Shree Joshi, Yi Cheng, Raphael Sandaltzopoulos, Hyun-Jeong Ra, Gwern Danet-Desnoyers, Daniel J. Powell, Jr, and Nathalie Scholler</td>
<td>Blockade of inhibitory T-cell receptor signals in the same general family as the CTLA-4 molecule targeted by ipilimumab (Yervoy) may offer a paradigm for simultaneous targeting of not only tumor cells, but also tumor-associated macrophages that drive immune escape.</td>
</tr>
<tr>
<td>4830</td>
<td>Transcription Poisoning by Topoisomerase I Is Controlled by Gene Length, Splice Sites, and miR-142-3p</td>
<td>Stéphanie Solier, Michael C. Ryan, Scott E. Martin, Sudhir Varma, Kurt W. Kohn, Hongfeng Liu, Barry R. Zeeberg, and Yves Pommier</td>
<td>Camptothecins used in cancer therapy may act to a major extent by targeting a p53-dependent microRNA.</td>
</tr>
<tr>
<td>4840</td>
<td>C-RAF Mutations Confer Resistance to RAF Inhibitors</td>
<td>Rajee Antony, Caroline M. Emery, Allison M. Sawyer, and Levi A. Garraway</td>
<td>These findings may provide a rationale for the future development of allosteric or pan-RAF inhibitors that disrupt the RAF dimerization interface.</td>
</tr>
<tr>
<td>4850</td>
<td>Pivotal Role of the Lipid Raft SK3–Orail Complex in Human Cancer Cell Migration and Bone Metastases</td>
<td>Aurélie Chantôme, Marie Potier-Cartereau, Lucie Clarysse, Gaëlle Fromont, Séverine Marionneau-Lambot, Maxime Guéguinou, Jean-Christophe Pagès, Christine Collin, Thibauld Oullier, Alban Girault, Flavie Arbion, Jean-Pierre Haelters, Paul-Alain Jaffrès, Michelle Pinault, Pierre Besson, Virginie Joulin, Philippe Bougnoux, and Christophe Vandier</td>
<td>This study links a therapeutically targetable potassium channel to bone metastasis, a common feature of advanced breast and prostate cancers that is generally untreatable.</td>
</tr>
</tbody>
</table>
LIIV28 Expression in Malignant Germ Cell Tumors Downregulates let-7 and Increases Oncogene Levels

Précis: This study defines a common oncogenic pathway in malignant germ cell tumors (GCT) and offers preclinical initial proof of concept for its targeting potential in this setting.

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
Xiaomei Zhang, Sofie Claerhout, Aleix Pratt, Lacey E. Dobrolecki, Ivana Petrovic, Qing Lai, Melissa D. Landis, Lisa Wiechmann, Rachel Schaff, Maria Giuliano, Helen Wong, Suzanne W. Fuqua, Edward S. Chen, Pavel Zuloaga, Chad A. Shaw, Michael T. Lewis

Précis: This well-characterized collection of human breast cancer xenografts will serve as a foundation for conduct of "animal clinical trials" to evaluate experimental therapeutics, as well as a resource for mechanistic studies of treatment resistance and metastasis.

elf4B Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by Abl Oncogenes
Jianling Yang, Jun Wang, Ke Chen, Guijie Guo, Ruijiao Xi, Paul B. Rothman, Douglas Whitten, Lianfeng Zhang, Shile Huang, and Ji-Long Chen

Précis: Results identify the translation initiation factor elf-4B as a critical substrate of Pim kinases, which mediate the activity of Abl oncogenes, suggesting this factor as a candidate therapeutic target in Abl-induced cancers.

Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Yaqing Zhang, John P. Morris IV, Wei Yan, Heather K. Schofield, Austin Gurney, Diane M. Simeone, Sarah E. Millar, Timothy Hoey, Matthias Hebrok, and Marina Pasca di Magliano

Précis: This study establishes a causal role for WNT pathway signaling in the development and progression of K-ras-initiated pancreatic cancers, with therapeutic implications for the use of WNT pathway antagonists in this deadly disease.

TRAF6 Upregulates Expression of HIF-1α and Promotes Tumor Angiogenesis
Heng Sun, Xue-Bing Li, Ya Meng, Li Fan, Min Li, and Jing Fang

Précis: A factor well studied in the TNF response and implicated in innate and adaptive immune control is established in this study to control tumor angiogenesis.

Retraction: Sp100 as a Potent Tumor Suppressor: Accelerated Senescence and Rapid Malignant Transformation of Human Fibroblasts through Modulation of an Embryonic Stem Cell Program

Correction: IKK4a/ARF Inactivation with Activation of the NF-κB/IL-6 Pathway Is Sufficient to Drive the Development and Growth of Angiosarcoma
ABOUT THE COVER

Schematic representation of the IRE1α-dependent activation loop that controls tumor cell adaptation. Tumor cell is presented in light gray, stromal cells in dark gray. Proteins are represented by circles, with upregulation in green and downregulation in red. Connections following stress-mediated activation of IRE1α are presented in green for activation and red for inhibition. For details, see article by Pluquet and colleagues on page 4732.